GRFS - Grifols, S.A.
| Previous Close | 22.55 |
| Open | 22.52 |
| Bid | 22.49 x 1000 |
| Ask | 22.50 x 800 |
| Day's Range | 22.36 - 22.55 |
| 52 Week Range | 19.92 - 25.18 |
| Volume | 173,854 |
| Avg. Volume | 753,754 |
| Market Cap | 18.321B |
| Beta | 1.39 |
| PE Ratio (TTM) | 37.80 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.42 (1.84%) |
| Ex-Dividend Date | 2017-12-01 |
| 1y Target Est | N/A |
- PR Newswire•10 days ago
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents
- Grifols conventional antisera reagents recently received licensing approval by the U.S. Food & Drug Administration for manual testing in immunohematology laboratories - The addition of antisera reagents ...
- PR Newswire•last month
Grifols donates over 25 million international units of blood clotting factor in 2017
BARCELONA, Spain, April 16, 2018 /PRNewswire/ -- Today, Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced it has donated over 25 million international units (IU) of blood clotting factor medicines over the last year. This donation is part of Grifols' commitment to provide a minimum of 200M IU to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over eight years starting in 2014. An estimated 400,000 people around the world have hemophilia, yet only 25% receive adequate treatment.
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications, Grifols, S.A, and Orthofix International N.V — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- PR Newswire•2 months ago
Grifols 2017 Annual Report on Form 20-F filed with the SEC on April 6, 2018
BARCELONA, Spain , April 6, 2018 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2017 Annual Report on Form 20-F with the United ...
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for B Communications, Student Transportation, Aurinia Pharmaceuticals, Grifols, S.A., NEXEO SOLUTIONS, and ASML Holding N.V. — Fundamental Analysis, Key Performance Indications
NEW YORK, March 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- PR Newswire•3 months ago
Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
- The FDA approval received in 2017 allows Grifols to market its Normal Saline solution in 500mL polypropylene bags in the U.S. to mitigate the current shortage of Normal Saline in this market - This agreement ...
- PR Newswire•3 months ago
Grifols Shines Light on Rare Disease with Launch of Educational Campaign "Look Into Genetic COPD"
Alpha-1 is often overshadowed by patients' smoking history, even though guidelines from the World Health Organization, the American Thoracic Society, and the COPD Foundation recommend testing all people with COPD for alpha-1, regardless of their age or smoking history. "Alpha-1 is a debilitating rare disease that is often overlooked," said Bill Zabel, President, Grifols North America Sales and Commercial Operations.
- PR Newswire•4 months ago
Grifols HyperRAB® (rabies immune globulin ) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
BARCELONA, Spain, Feb. 6, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and immune globulin products for patients, has received approval from the U.S. Food & Drug Administration (FDA) for a new higher potency formulation of its HyperRAB® rabies immune globulin [human] for rabies postexposure prophylaxis (treatment of a person immediately after exposure to the rabies virus). The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options, offering a greater concentration of anti-rabies virus antibodies within each mL of volume, and for patients, the potential for fewer injections by significantly reducing the volume of medication administered in each dose.
- PR Newswire•6 months ago
Grifols Misterium® Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation
Grifols is now exclusive distributor for airinspace® air decontamination and surface disinfection technologies BARCELONA, Spain , Dec. 4, 2017 /PRNewswire/ -- Grifols is the exclusive U.S. distributor ...
- PR Newswire•9 months ago
Grifols Phocus Rx® Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces
Phocus Rx® is Live with Bidirectional Interfaces with Three of the Top Five Hospital Information Systems in the US BARCELONA, Spain , Aug. 22, 2017 /PRNewswire/ -- Phocus Rx ® enhances safety and improves ...
- PR Newswire•10 months ago
Select American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols' Procleix Babesia Assay Under an Investigational New Drug Protocol
- American Red Cross is testing selected donations collected in areas of the U.S. that are endemic for the tick known to carry the Babesia parasite - The data collected will be used in the submission process ...
- PR Newswire•11 months ago
Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples
BARCELONA, Spain, June 22, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, and a leader in the development of innovative diagnostic solutions, is expanding its Texas-based Clinical Diagnostics Laboratory menu by launching therapeutic drug monitoring testing services. As the standard of care changes towards individualized patient care in diseases such as inflammatory bowel diseases, the clinicians' demand for monitoring biologic drugs is growing.
- PR Newswire•11 months ago
Grifols and Beckman Coulter Enter into an Exclusive Distribution Agreement
BARCELONA, June 12, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, and Beckman Coulter Inc., a leading provider of innovative, efficient and reliable diagnostics solutions, have entered into an exclusive, long-term agreement for the global distribution of Grifols' hemostasis instruments, reagents and consumables. "Grifols continues to execute its strategy in growing the Specialty Diagnostics line. "Beckman Coulter's long-term partnership with Grifols expands our extensive diagnostic product offering and further supports our position as a partner of choice with hospitals and clinical laboratories across the world," stated Arnd Kaldowski, President of Beckman Coulter Diagnostics.